Figure 6. C4-27z and C4opt-27z RNA CAR T cells completely eliminate widely disseminated tumors in vivo.

A. NSG mice bearing disseminated SKOV3 tumor were treated with one intraperintoneal injection of 2 × 10⁷ CAR⁺ T cells on day 14 (loading dose) followed by a lower maintenance dose of 10⁷ CAR⁺ T cells on days 21 and 28. B. Tumor growth was assessed by SKOV3 fLUC⁺ bioluminescence, which demonstrates complete tumor remission in all C4-27z and C4opt-27z CAR T lymphocyte treated, tumor-bearing animals (2-way ANOVA, p < .001). C. CD4⁺ and CD8⁺ C4-27z and C4opt-27z CAR T cells were initially present at low numbers in peripheral circulation, suggesting FRα-specific CAR T cell migration to specific tumor locales. D–E. Conversely, successive administration of C4-27z and C4opt-27z CAR T cells resulted in extensive CD4⁺ and CD8⁺ T cell proliferation in peripheral blood during the course of therapy.